Compare iShares 20 Plus Year Treasury Bond ETF (TLT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $78.89, up 1.08% on the day but remains in a prolonged downtrend, having fallen 46% over five years. Technical indicators are bearish overall, with moving averages and oscillators signaling selling pressure. The fund continues to face headwinds from rising Treasury yields, which recently hit multi-decade highs, though recent PCE data provided some relief.

The outlook for TLT hinges on the direction of long-term interest rates. While current yields near 5.3% offer attractive income, further rate increases could pressure prices lower. Key risks include persistent inflation and Fed policy uncertainty. Investors should weigh high yield against potential capital depreciation in a rising rate environment.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.